| Bioactivity | ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of HIV via selectively binding to BD1 domain of BRD4. ZL0580 induces HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter[1][2][3]. | ||||||||||||
| Invitro | ZL0580 (8 μM, 2 days, PBMCs of viremic HIV-infected individuals) induces HIV transcriptional suppression with low toxicity[1].ZL0580 treatment (10 μM) suppresses both PMA-stimulated and basal HIV transcription[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | ZL0580 | ||||||||||||
| CAS | 2377151-10-3 | ||||||||||||
| Formula | C25H23F3N4O4S | ||||||||||||
| Molar Mass | 532.53 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Niu Q, et al. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. J Clin Invest. 2019 Jul 22;129(8):3361-3373. [2]. Vansant G, et al. Block-And-Lock Strategies to Cure HIV Infection. Viruses. 2020 Jan 10;12(1). pii: E84. [3]. Brasier AR, et al. Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling. Drug Discov Today. 2020 Jan;25(1):126-132. |
ZL0580
CAS: 2377151-10-3 F: C25H23F3N4O4S W: 532.53
ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of HIV via selectively binding to BD1 doma
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.